EcoDrugPlus

C-C Motif Chemokine Receptor 2

Ensembl ID : ENSCDRG00005005891
Gene Symbol: CCR2
3 Cross references
150 Possible Orthologues:

C-C Motif Chemokine Receptor 4

Ensembl ID : ENSCDRG00005012095
Gene Symbol: CCR4
3 Cross references
113 Possible Orthologues:

C-C Motif Chemokine Receptor 5

Ensembl ID : ENSCDRG00005005900
Gene Symbol: CCR5
3 Cross references
152 Possible Orthologues:

C-C Motif Chemokine Receptor 9

Ensembl ID : ENSCDRG00005005748
Gene Symbol: CCR9
3 Cross references
265 Possible Orthologues:

C-X-C Chemokine Receptor Type 2

Ensembl ID : ENSCDRG00005007321
Gene Symbol: LOC105096070
2 Cross references
272 Possible Orthologues:

C-X-C Motif Chemokine Ligand 8

Ensembl ID : ENSCDRG00005020011
Gene Symbol: CXCL8
3 Cross references
179 Possible Orthologues:

C-X-C Motif Chemokine Receptor 4

Ensembl ID : ENSCDRG00005018891
Gene Symbol: CXCR4
3 Cross references
218 Possible Orthologues:

Cf Transmembrane Conductance Regulator

Ensembl ID : ENSCDRG00005002205
Gene Symbol: CFTR
3 Cross references
217 Possible Orthologues:

Dna Methyltransferase 1

Ensembl ID : ENSCDRG00005006428
Gene Symbol: DNMT1
3 Cross references
212 Possible Orthologues:

Dna Topoisomerase I

Ensembl ID : ENSCDRG00005009676
Gene Symbol: TOP1
3 Cross references
273 Possible Orthologues:

Dna Topoisomerase Ii Alpha

Ensembl ID : ENSCDRG00005007292
Gene Symbol: TOP2A
3 Cross references
206 Possible Orthologues:

Dna Topoisomerase Ii Beta

Ensembl ID : ENSCDRG00005003802
Gene Symbol: TOP2B
3 Cross references
210 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).